All editorial matter in CMAJ represents the opinions of the authors and not necessarily those
of the Canadian Medical Association. trast to previous reports of screening in the general …

OBJECTIVE: To evaluate the efficacy and safety of 2 years' treatment of moderate benign
prostatic hyperplasia (BPH) with finasteride. DESIGN: Double-blind, parallel-group, placebo …

The treatment of benign prostatic hyperplasia (BPH) has changed dramatically over the past
10 years. Phase 3 studies of the safety and effectiveness of α-blockers (eg, terazosin and …

OBJECTIVES: To evaluate the safety and efficacy of finasteride 5 mg during a 10-year
period in men with enlarged prostates from a single center who participated in the double …

Benign prostatic hyperplasia (BPH) is a common disorder in men with an incidence that
increases with age. BPH often requires therapy when patients begin to experience lower …

Benign prostatic hyperplasia (BPH), commonly known as “enlarged prostate,” is a
noncancerous growth of the prostate gland that affects a large proportion of men over the …

Key words: Alpha blocker, Benign prostatic hyperplasia, Finasteride In a 1999 review article,
we detailed the evolution of the medical management of benign prostatic hyperplasia (BPH) …

Medical therapy for benign prostatic hyperpla-sia (BPH) has become the most widely
accepted first-line therapy for symptomatic men with BPH. Alpha-blockade and 5-alpha …

Prostate cancer is the most common non-skin cancer in the United States, the second
leading cause of death from cancer among US men, and the seventh leading cause of death …

Men with moderate symptoms of benign prostatic hyperplasia (BPH) are the best candidates
for medical treatment, while surgery is usually indicated for patients with severe symptoms …